- Home
- WATT vs BLRX Comparison
WATT vs BLRX Comparison
Compare WATT & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WATT | BLRX |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | Israel |
| Employees | N/A | 28 |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.6M |
| IPO Year | 2014 | 2011 |
Fundamental Metrics
Financial Performance| Metric | WATT | BLRX |
|---|---|---|
| Price | $3.72 | $2.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 83.5K | 23.2K |
| Earning Date | 11-12-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,018,000.00 | ★ $12,735,000.00 |
| Revenue This Year | $509.64 | N/A |
| Revenue Next Year | $210.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 600.23 | N/A |
| 52 Week Low | $3.62 | $2.30 |
| 52 Week High | $81.00 | $14.70 |
Technical Indicators
Market Signals| Indicator | WATT | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 23.82 | 39.72 |
| Support Level | $3.91 | $2.85 |
| Resistance Level | $4.74 | $3.03 |
| Average True Range (ATR) | 0.45 | 0.17 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 3.04 | 18.39 |
Price Performance
Historical ComparisonAbout WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs, and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. The WPN technology provides a comprehensive suite of capabilities designed to power the next generation of wireless energy networks, seamlessly delivering power and data across diverse, battery-free device ecosystems. It enhances operational visibility, control, and intelligent business automation. Its products include Transmitter IC & Module, Receivers IC, Transmitter System, and Evaluation Kits.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.